Fresenius SE & Co. KGaA is a diversified global healthcare company based in Germany, providing a wide range of products and services for critically and chronically ill patients. The company operates through two primary business segments: Fresenius Helios and Fresenius Kabi. Fresenius Helios is Europe's leading private hospital operator, managing an extensive network of acute care hospitals, outpatient clinics, and occupational health centers, primarily in Germany and Spain (through Quirónsalud). In 2023, Helios generated approximately €10.0 billion, representing nearly 50% of the group's total revenue. Fresenius Kabi, contributing around 37% of revenue (€7.5 billion), specializes in lifesaving medicines and technologies, including intravenous generic drugs, clinical nutrition, biopharmaceuticals, and infusion therapies.
Historically, the group also included Fresenius Medical Care (FMC), the world's largest provider of dialysis products and services, but FMC was deconsolidated in late 2023 as part of the company's strategic realignment. Additionally, the company announced a structured exit from its Fresenius Vamed segment (hospital project management and services, ~10% of 2023 revenue) in 2024 to further streamline operations. Geographically, Fresenius has a strong footprint in Europe, which accounts for the majority of its revenue, while also maintaining significant operations in North America, Latin America, and the Asia-Pacific region. The company's competitive position is anchored by its vertically integrated model, combining direct patient care through its vast hospital network with the manufacturing of essential medical supplies and pharmaceuticals.
